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incidence
The estimated incidence of cancer diagnosed in pregnant
women in developed societies is 1:1000 pregnancies and is
predicted to rise as childbearing is shifted towards the late
reproductive age. The most common cancers associated with
pregnancy are cervical, breast cancer, melanoma, lymphomas
and acute leukemias (Table 1).
diagnosis and staging
The diagnostic work-up should include a thorough physical
examination, including the pelvis, breasts, lymph nodes, skin
and should limit unnecessary exposure to ionizing radiation.
Fine needle aspiration, core needle or open excisional biopsies
are safe to perform. Chest X-ray and mammography with
abdominal shielding and ultrasonic examinations are the
cornerstone of a basic staging, supplemented by MRI scans in
the second/third trimesters when needed [IV, B]. In view of the
theoretical risk of fetal heating/cavitation, first trimester MRI
scans should be done sparingly and the potentially teratogenic
gadolinium should not be administered [V, D]. Computerized
tomography or radioisotope studies should be avoided.
Minor staging procedures (spinal tap, bone marrow biopsy,
endoscopies) are relatively safe to perform [IV, B].
risk assessment
Ionizing radiation and cytotoxic agents have potential
mutagenic, teratogenic and carcinogenic effects for the embryo,
depending on dose, nature of compound, treatment field and
gestational stage (Table 2).
Fetal exposure to radiation doses in excess of 5–10 cGy
should be avoided. This threshold dose is associated with a very
low risk of stochastic biologic effects (mutations) and does not
cause non-stochastic effects (malformations, developmental
disorders). Exposure to antineoplastic agents should be avoided
during the first trimester (organogenesis).
treatment and follow-up
The optimal therapeutic strategy should be jointly chosen by
the medical team, patient and family and will depend on
gestational age, nature and stage of cancer, treatment options
and patient wishes. The medical team should include an
obstetrician, a neonatologist, a medical oncologist, a surgeon
and a psychologist and the patient should be treated at major
hospitals with the required expertise and infrastructure.
Pregnancy termination is advised in the case of
chemotherapy or radiotherapy administration during the first
trimester, need for radical gynecologic surgery, poor maternal
life expectancy.
cytotoxic chemotherapy
Chemotherapy can be administered during the second and
third trimesters with reasonable safety, though there is an
increased risk of still birth, growth retardation and premature
delivery [III, B]. Older-generation alkylators (thiotepa,
busulfan, chlorambucil, nitrogen mustard) and antimetabolites
(aminopterin, methotrexate) have the most pronounced
teratogenic and abortive potential, while anthracyclines, 5-
fluorouracil, cytarabine and vinca alkaloids the least. Emerging
evidence from a small number of case reports suggests that
taxanes and platinum compounds are relatively safe to
administer beyond the first gestational trimester [IV, C]. There
are no data on pemetrexed, gemcitabine, vinorelbine.
targeted agents
Only a few pregnant women have inadvertently been exposed
to targeted agents. Trastuzumab caused oligohydramnios in
four and abnormal implantation in one out of seven pregnant
women, while rituximab only caused transient neonatal
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lymphopenia in four reported cases. Imatinib was occasionally
associated with low birth weight and premature delivery in 29
reported cases, though one case of hypospadias and one of
meningocele have been published as well. In view of lack of data
and past experience with the antiangiogenic agent thalidomide,
administration of targeted agents modulating angiogenesis
(bevacizumab, sunitinib, sorafenib) should be avoided in
pregnant women [V, D].
surgery, radiation therapy and timing of delivery
Delivery should take place after weeks 32–35, 3 weeks after the
last chemotherapy cycle. Surgical operations can be safely
performed during the first two trimesters, with a slight to
moderate increase in the risk of abortion during the first
trimester, especially with abdominal operations. In the third
trimester, operation or deferral after delivery may be chosen
according to circumstances [IV, B]. Radiotherapy should be
administered post-partum and care should be taken to avoid
fetal exposure to ionizing irradiation of any source to <5–10
cGy [IV, C].
supportive therapy
Antiemetics (ondansetron, metoclopramide, meclozine) may
be safely administered with ommittance of corticosteroids in
the first trimester [II, B]. Analgesics (paracetamol, opioids,
anti-inflammatory agents) [IV, B] and growth cytokines [V, D]
have been administered in pregnant women beyond the first
trimester without untoward effects, though some risk of fetal
respiratory depression and ductus arteriosus closure exists.
Biphosphonates and tamoxifen, aromatase inhibitors,
somatostatin should be deferred after delivery. Breast feeding
should be avoided during chemotherapy.
Although placental/fetal metastases are exceedingly rare,
histological examination of the placenta after delivery should
take place.
follow-up
The follow-up of women diagnosed with cancer during
pregnancy and their offspring should adhere to common
standards. Most cohort studies showed that the outcome of
pregnant cancer patients is not significantly inferior to non-
pregnant patients matched for age and stage of cancer, though
some series reported inferior survival of pregnant women with
cancer. Still, it is currently unknown whether the latter finding
is due to more aggressive cancer biology during gestation or
simply due to undertreatment of these patients.
There is no evidence to establish that patient outcome is
compromised by future pregnancies [III, B]. Most cohort
studies have shown that women with a history of breast cancer
who later become pregnant are at a reduced risk of malignant
relapse/death. This finding should be interpreted with caution,
as healthy women are the ones who attempt pregnancy, while
those who experience a malignant relapse do not.
To date, there is no evidence establishing that in utero
exposure to chemotherapy (beyond the first trimester) or
radiotherapy (doses <10–20 cGy) compromises the long-term
physical and mental development of children [IV, B].
Most oncologists would recommend that potentially cured
breast cancer patients postpone childbearing for at least 2–3
years, the median time to recurrence for relapsing women.
fertility preservation
The gonadotoxic effects of ionizing radiation, chemotherapy
and surgery depend on patient age, treatment fields, total dose
and nature of insulting agents (Table 3).
Conservative or modified abdominopelvic/genitourinary
surgery should only be implemented if it does not compromise
patient outcome. All patients at risk for infertility who have not
completed childbearing should discuss germ cell storage
options with the medical team.
Available interventions for male fertility preservation are
unlikely to delay cancer treatment. Semen cryopreservation of
at least three samples with 48-h abstinence intervals is
recommended for men [III, A]. For azoospermic men,
testicular sperm extraction may be an option for fertility
preservation [V, D]. Prepubertal males may participate in
clinical research of testicular tissue/spermatogonial stem cell
storage. No studies support the effectiveness of male gonadal
protection by means of hormonal manipulations during
chemotherapy or radiotherapy.
Female fertility preservation procedures have requirements
for scheduling and ovarian stimulation, resulting in a likely
Table 1. Incidence of tumor types in pregnant women
Malignancy Incidence (per no. of gestations)
Malignant melanoma 1:1000–10 000
Breast carcinoma 1:3000–1:10 000
Carcinoma of the cervix 1:2000–10 000
Lymphoma 1:1000–1:6000
Leukemia 1:75 000–1:100 000
Ovarian carcinoma 1:10 000–1:100 000
Colon cancer 1:13 000
Table 2. Gestational stage and effects of antineoplastic therapy
Gestational stage Embryonal/fetal development Impact
Weeks 0–2 Undifferentiated multicellular organism ‘All or nothing’, spontaneous abortion or normal development
Weeks 3–12 Organogenesis Spontaneous abortion, major congenital anomalies
2nd and 3rd trimesters Intrauterine growth and maturation, continuing
development of CNS, gonads,
teeth–palate, eyes, ears
Functional defects and minor anomalies of late-forming tissues,
still birth, intrauterine growth retardation, premature delivery,
myelosuppression
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delay of 2–6 weeks of cancer treatment initiation. Embryo
cryopreservation and ovary transposition are the only
established fertility preservation options for female patients,
live birth rates being inferior to fresh embryo procedures.
Menstrual function resumes in 50% of women undergoing
ovarian transposition, due to ischemia and scatter radiation
[III, A]. Short-term ovarian stimulation with gonadotrophins is
necessary for oocyte retrieval and may be associated with
a theoretical risk of growth of hormone-sensitive tumors.
Emerging evidence on alternative (letrozole or tamoxifen)
stimulation protocols is scant. Experimental fertility
preservation options are oocyte cryopreservation for women
without a partner and ovarian tissue storage for those who
cannot undergo ovarian stimulation or are prepubertal. Despite
>120 deliveries with oocyte storage, issues with oocyte damage,
DNA integrity and low yield of pregnancy urge us to consider
oocyte cryopreservation experimental. Ovarian tissue
reimplantation carries a low risk of reintroduction of cancer
cells if ovarian micrometastases were present.
Female gonadal protection from chemotherapy by means of
oral contraceptive or GnRH agonist administration was
effective in observational studies but should be considered
investigational until results of ongoing prospective randomized
trials become available [III, B].
Post-hoc subgroup analyses of prospective trials and three
meta-analyses showed that amenorrhea induced by
chemotherapy or GnRH-agonists, compared with menses
preservation, was associated with improved survival in
premenopausal women with resected hormone receptor-
positive breast cancer. However, permanent amenorrhea had
no advantage over a temporary one in terms of patient
outcome. Theses facts should be communicated to the patient
with hormone-responsive tumor who is considering
preservation of menses.
Aside from the risk of cancer relapse which may require
avoidance of childbearing for2–3 years, allmale and female patients
who remain fertile after cancer treatment should defer childbearing
for at least 12 months to ensure germ cell integrity [IV, C].
Women with a history of cancer/cancer treatment should be
considered high risk for perinatal complications (maternal
cardiac failure, miscarriage, low birth weight and prematurity
of the newborn) and receive specialized, close care. Though
poor DNA integrity has been reported in gametes of cancer
patients, in the setting of successful fertility preservation/
restoration there is no evidence that prior history of cancer or
cancer therapy increases the rates of malformations, functional
defects or malignancies in the patient’s offspring [V, D].
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the expert authors and the
ESMO faculty.
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